101 found
Order:
Disambiguations:
Jeffrey P. Kahn [32]Jeffrey Kahn [20]Jonathan Kahn [11]Joel S. Kahn [11]
J. Kahn [6]Jean Kahn [4]Journet Kahn [4]Joan Yess Kahn [3]

Not all matches are shown. Search with initial or firstname to single out others.

  1.  12
    James F. Childress, Ruth R. Faden, Ruth D. Gaare, Lawrence O. Gostin, Jeffrey Kahn, Richard J. Bonnie, Nancy E. Kass, Anna C. Mastroianni, Jonathan D. Moreno & Phillip Nieburg (2002). Public Health Ethics: Mapping the Terrain. Journal of Law, Medicine & Ethics 30 (2):170-178.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography   54 citations  
  2.  5
    Susan M. Wolf, Frances P. Lawrenz, Charles A. Nelson, Jeffrey P. Kahn, Mildred K. Cho, Ellen Wright Clayton, Joel G. Fletcher, Michael K. Georgieff, Dale Hammerschmidt, Kathy Hudson, Judy Illes, Vivek Kapur, Moira A. Keane, Barbara A. Koenig, Bonnie S. LeRoy, Elizabeth G. McFarland, Jordan Paradise, Lisa S. Parker, Sharon F. Terry, Brian van Ness & Benjamin S. Wilfond (2008). Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations. Journal of Law, Medicine & Ethics 36 (2):219-248.
    No consensus yet exists on how to handle incidental fnd-ings in human subjects research. Yet empirical studies document IFs in a wide range of research studies, where IFs are fndings beyond the aims of the study that are of potential health or reproductive importance to the individual research participant. This paper reports recommendations of a two-year project group funded by NIH to study how to manage IFs in genetic and genomic research, as well as imaging research. We conclude that researchers (...)
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography   27 citations  
  3.  5
    P. S. Duggan, A. W. Siegel, D. M. Blass, H. Bok, J. T. Coyle, R. Faden, J. Finkel, J. D. Gearhart, H. T. Greely, A. Hillis, A. Hoke, R. Johnson, M. Johnston, J. Kahn, D. Kerr & P. King (2009). Unintended Changes in Cognition, Mood, and Behavior Arising From Cell-Based Interventions for Neurological Conditions: Ethical Challenges. American Journal of Bioethics 9 (5):31-36.
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography   10 citations  
  4. Leili Fatehi, Susan M. Wolf, Jeffrey McCullough, Ralph Hall, Frances Lawrenz, Jeffrey P. Kahn, Cortney Jones, Stephen A. Campbell, Rebecca S. Dresser, Arthur G. Erdman, Christy L. Haynes, Robert A. Hoerr, Linda F. Hogle, Moira A. Keane, George Khushf, Nancy M. P. King, Efrosini Kokkoli, Gary Marchant, Andrew D. Maynard, Martin Philbert, Gurumurthy Ramachandran, Ronald A. Siegel & Samuel Wickline (2012). Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field. Journal of Law, Medicine and Ethics 40 (4):716-750.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography   4 citations  
  5. Susan M. Wolf, Frances P. Lawrenz, Charles A. Nelson, Jeffrey P. Kahn, Mildred K. Cho, Ellen Wright Clayton, Joel G. Fletcher, Michael K. Georgieff, Dale Hammerschmidt, Kathy Hudson, Judy Illes, Vivek Kapur, Moira A. Keane, Barbara A. Koenig, Bonnie S. LeRoy, Elizabeth G. McFarland, Jordan Paradise, Lisa S. Parker, Sharon F. Terry, Brian Van Ness & Benjamin S. Wilfond (2008). Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations. Journal of Law, Medicine and Ethics 36 (2):219-248.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography   7 citations  
  6.  31
    Allen E. Buchanan, Andrea Califano, Jeffrey Kahn, Elizabeth McPherson, John A. Robertson & Baruch A. Brody (2002). Pharmacogenetics: Ethical Issues and Policy Options. Kennedy Institute of Ethics Journal 12 (1):1-15.
    : Pharmacogenetics offers the prospect of an era of safer and more effective drugs, as well as more individualized use of drug therapies. Before the benefits of pharmacogenetics can be realized, the ethical issues that arise in research and clinical application of pharmacogenetic technologies must be addressed. The ethical issues raised by pharmacogenetics can be addressed under six headings: regulatory oversight, confidentiality and privacy, informed consent, availability of drugs, access, and clinicians' changing responsibilities in the era of pharmacogenetic medicine. We (...)
    Direct download (7 more)  
     
    Export citation  
     
    My bibliography   7 citations  
  7.  27
    Joel S. Kahn (1994). Reviews : Peter Wollen, Raiding the Icebox: Reflections on Twentieth Century Culture, (Indiana University Press, 1993). Thesis Eleven 39 (1):135-137.
    No categories
    Direct download (5 more)  
     
    Export citation  
     
    My bibliography  
  8.  1
    Baruch Brody, Nancy Dubler, Jeff Blustein, Arthur Caplan, Jeffrey P. Kahn, Nancy Kass, Bernard Lo, Jonathan Moreno, Jeremy Sugarman & Laurie Zoloth (2002). The Task Force Responds. Hastings Center Report 32 (3):22-23.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography   7 citations  
  9.  24
    Joan Yess Kahn (1980). Modes of Medical Instruction. Semiotics:227-230.
    No categories
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography  
  10.  11
    Leili Fatehi, Susan M. Wolf, Jeffrey McCullough, Ralph Hall, Frances Lawrenz, Jeffrey P. Kahn, Cortney Jones, Stephen A. Campbell, Rebecca S. Dresser, Arthur G. Erdman, Christy L. Haynes, Robert A. Hoerr, Linda F. Hogle, Moira A. Keane, George Khushf, Nancy M. P. King, Efrosini Kokkoli, Gary Marchant, Andrew D. Maynard, Martin Philbert, Gurumurthy Ramachandran, Ronald A. Siegel & Samuel Wickline (2012). Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field. Journal of Law, Medicine & Ethics 40 (4):716-750.
    The nanomedicine field is fast evolving toward complex, “active,” and interactive formulations. Like many emerging technologies, nanomedicine raises questions of how human subjects research (HSR) should be conducted and the adequacy of current oversight, as well as how to integrate concerns over occupational, bystander, and environmental exposures. The history of oversight for HSR investigating emerging technologies is a patchwork quilt without systematic justification of when ordinary oversight for HSR is enough versus when added oversight is warranted. Nanomedicine HSR provides an (...)
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography   1 citation  
  11.  4
    Jeffrey P. Kahn (2006). What Happens When Politics Discovers Bioethics? Hastings Center Report 36 (3):10-10.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography   2 citations  
  12.  10
    Susan M. Wolf & Jeffrey P. Kahn (2005). Bioethics Matures:. Hastings Center Report 35 (4):22-24.
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography   2 citations  
  13. James F. Childress, Ruth R. Faden, Ruth D. Gaare, Lawrence O. Gostin, Jeffrey Kahn, Richard J. Bonnie, Nancy E. Kass, Anna C. Mastroianni, Jonathan D. Moreno & Phillip Nieburg (2002). Public Health Ethics: Mapping the Terrain. Journal of Law, Medicine and Ethics 30 (2):170-178.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography   3 citations  
  14.  6
    John A. Robertson, Jeffrey P. Kahn & John E. Wagner (2002). CONCEPTION to Obtain Hematopoietic Stem Cells. Hastings Center Report 32 (3):34-40.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography   2 citations  
  15.  41
    Jeffrey P. Kahn & Anna C. Mastroianni (2004). Creating a Stem Cell Donor: A Case Study in Reproductive Genetics. Kennedy Institute of Ethics Journal 14 (1):81-96.
    : During the nearly 10 years since its introduction, preimplantation genetic diagnosis (PGD) has been used predominantly to avoid giving birth to a child with identified genetic disease. Recently, PGD was used by a couple not only to test IVF-created embryos for genetic disease, but also to test for a nondisease trait related to immune compatibility with a child in the family in need of an hematopoetic stem cell transplant. This article describes the case, raises some ethical and policy issues, (...)
    Direct download (6 more)  
     
    Export citation  
     
    My bibliography   1 citation  
  16.  12
    Joan R. Kahn, Shyam Thapa & H. W. Gaminiratne (1989). Sociodemographic Determinants of Contraceptive Method Choice in Sri Lanka: 1975–82. Journal of Biosocial Science 11:41-60.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography  
  17.  10
    Susan M. Wolf, Jeffrey P. Kahn & John E. Wagner (2003). Using Preimplantation Genetic Diagnosis to Create a Stem Cell Donor: Issues, Guidelines & Limits. Journal of Law, Medicine & Ethics 31 (3):327-339.
  18.  39
    Jeffrey P. Kahn (2003). Three Views of Organ Procurement Policy: Moving Ahead or Giving Up? Kennedy Institute of Ethics Journal 13 (1):45-50.
    : The supply of organs for transplant remains inadequate to meet the needs of waiting patients, in spite of many programs and approaches to increase rates of donation. Over the years there have been numerous proposals to introduce schemes that would move toward the outright sale of organs. Three articles in this issue of the Journal propose methods for increasing organ supply—two by moving toward a market approach and the third by advocating a change in social culture. All three suffer (...)
    Direct download (6 more)  
     
    Export citation  
     
    My bibliography   1 citation  
  19.  4
    Jean Kahn (2009). A Propos d'Une Correction À Apporter du Texte d'Une Définition du Beau Dans la Critique de la Faculté de Juger. Kant-Studien 100 (1):106-106.
  20.  4
    Jeffrey P. Kahn (1991). Genetic Harm: Bitten by the Body That Keeps You? Bioethics 5 (4):289–308.
    Direct download (6 more)  
     
    Export citation  
     
    My bibliography   4 citations  
  21.  16
    James A. Kahn, Steven E. Landsburg & Alan C. Stockman (1992). On Novel Confirmation. British Journal for the Philosophy of Science 43 (4):503-516.
    Evidence that confirms a scientific hypothesis is said to be ‘novel’ if it is not discovered until after the hypothesis isconstructed. The philosophical issues surrounding novel confirmation have been well summarized by Campbell and Vinci [1983]. They write that philosophers of science generally agree that when observational evidence supports a theory, the confirmation is much stronger when the evidence is ‘novel’... There are, nevertheless, reasons to be skeptical of this tradition... The notion of novel confirmation is beset with a theoretical (...)
    Direct download (9 more)  
     
    Export citation  
     
    My bibliography   3 citations  
  22.  5
    Anna Mastroianni & Jeffrey Kahn (2001). Swinging on the Pendulum: Shifting Views of Justice in Human Subjects Research. Hastings Center Report 31 (3):22-24.
    Direct download (5 more)  
     
    Export citation  
     
    My bibliography   2 citations  
  23.  15
    Susan M. Wolf & Jeffrey P. Kahn (2005). Bioethics Matures: The Field Faces the Future. Hastings Center Report 35 (4):22-24.
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography  
  24.  26
    Robert E. McKeown, Douglas L. Weed, Jeffrey P. Kahn & Michael A. Stoto (2003). American College of Epidemiology Ethics Guidelines: Foundations and Dissemination. Science and Engineering Ethics 9 (2):207-214.
    Epidemiology is a core science of public health, focusing on research related to the distribution and determinants of both positive and adverse health states and events and on application of knowledge gained to improve public health. The American College of Epidemiology (ACE) is a professional organization devoted to the professional practice of epidemiology. As part of that commitment, and in response to concerns for more explicit attention to core values and duties of epidemiologists in light of emerging issues and increased (...)
    Direct download (7 more)  
     
    Export citation  
     
    My bibliography   1 citation  
  25.  8
    E. Vayena, R. Brownsword, S. J. Edwards, B. Greshake, J. P. Kahn, N. Ladher, J. Montgomery, D. O'Connor, O. O'Neill, M. P. Richards, A. Rid, M. Sheehan, P. Wicks & J. Tasioulas (forthcoming). Research Led by Participants: A New Social Contract for a New Kind of Research. Journal of Medical Ethics.
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography  
  26.  18
    Jonathan Kahn (2003). Getting the Numbers Right: Statistical Mischief and Racial Profiling in Heart Failure Research. Perspectives in Biology and Medicine 46 (4):473-483.
  27. Stella Gonzalez Arnal, Donald Chalmers, David Kum-Wah Chan, Margaret Coffey, Jo Ann T. Croom, Mylène Deschênes, Henrich Ganthaler, Yuri Gariev, Ryuichi Ida, Jeffrey P. Kahn, Martin O. Makinde, Anna C. Mastroianni, Katharine R. Meacham, Bushra Mirza, Michael J. Morgan, Dianne Nicol, Edward Reichman, Susan E. Wallace & Larissa P. Zhiganova (2004). Cross-Cultural Biotechnology: A Reader. Rowman & Littlefield Publishers.
    This book is a rich blend of analyses by leading experts from various cultures and disciplines. A compact introduction to a complex field, it illustrates biotechnology's profound impact upon the environment and society. Moreover, it underscores the vital relevance of cultural values. This book empowers readers to more critically assess biotechnology's value and effectiveness within both specific cultural and global contexts.
     
    Export citation  
     
    My bibliography   1 citation  
  28. John A. Robertson, Jeffrey P. Kahn & John E. Wagner (forthcoming). Conception. Hastings Center Report.
     
    Export citation  
     
    My bibliography  
  29.  9
    Jonathan Kahn (2005). Ethnic Drugs. Hastings Center Report 35 (1):c3-c3.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography   1 citation  
  30.  7
    H. Peter Spielmann, Jason D. Kahn & John E. Hearst (1986). New Methods for Probing Nucleic Acids. Bioessays 5 (5):232-234.
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography  
  31.  11
    Joel S. Kahn (1997). Malaysian Modern or Anti-Anti Asian Values. Thesis Eleven 50 (1):15-33.
    Probably the most influential critique of social theorizing about the non-West in recent years has been one emanating from a `subalternist' perspective, by which I mean a critique mounted if not by, then in the name of, peoples/cultures/modes of thought that have been dominated culturally by `the West'. The rapid rise to prominence - economic, political, strategic and cultural - of an increasingly large number of nation states in the Asia-Pacific region poses a rather different kind of challenge to western (...)
    No categories
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography  
  32.  2
    Jeffrey Kahn & Anna Mastroianni (2004). Looking Forward in Bioethics. Journal of Law, Medicine & Ethics 32 (2):196-197.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography   1 citation  
  33.  29
    Jonathan Kahn (2005). "Ethnic Drugs&Quot. Hastings Center Report 35 (1):c3-c3.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography  
  34.  6
    Jeffrey Kahn (2014). Lessons Learned: Challenges in Applying Current Constraints on Research on Chimpanzees to Other Animals. Theoretical Medicine and Bioethics 35 (2):97-104.
    The Institute of Medicine (IOM) Committee on the Necessity of the Use of Chimpanzees in Biomedical and Behavioral Research made a series of recommendations that, as of an announcement on June 26, 2013, the National Institutes of Health (NIH) is turning into implemented guidelines. Many advocates, including some researchers and scholars, have suggested that the Committee’s recommendations could be applied successfully to other animal species. This article examines, from my perspective as the IOM Committee’s chair, some of the most important (...)
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography  
  35.  7
    Joel S. Kahn & Francesco Formosa (2002). The Problem of `Crony Capitalism': Modernity and the Encounter with the Perverse. Thesis Eleven 69 (1):47-66.
    This article provides some reflections on the problem posed by ostensibly perverse phenomena like political patronage, corruption and crony capitalism for modernising narratives, which are currently enjoying a renewed popularity. In the light of an ethnographic example from Indonesia, it is argued that the continual attempt to relocate such phenomena to terrains not properly modern precludes the possibility of serious analysis or moral/political assessment of these phenomena. The starting point for any genuine engagement with these issues is the recognition that (...)
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography  
  36. Susan M. Wolf, Jeffrey P. Kahn & John E. Wagner (2003). Using Preimplantation Genetic Diagnosis to Create a Stem Cell Donor: Issues, Guidelines & Limits. Journal of Law, Medicine and Ethics 31 (3):327-339.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    My bibliography   1 citation  
  37.  1
    Jeffrey Kahn (2002). Commentary: Making the Most of Strangers' Altruism. Journal of Law, Medicine & Ethics 30 (3):446-447.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography   1 citation  
  38.  8
    Journet Kahn (1956). The Threat to Academic Freedom. Proceedings of the American Catholic Philosophical Association 30:160-170.
  39.  11
    Jonathan Kahn (2012). The Troubling Persistence of Race in Pharmacogenomics. Journal of Law, Medicine & Ethics 40 (4):873-885.
    This article is concerned about what may be happening to race and medicine in the “meantime” between today's clinical realities and the promised land of pharmacogenomics where the need for using race in medicine is supposed to fade away. It argues that previous debates over the use of race in medicine are being side-stepped as race is being reconfigured from a “crude surrogate” for genetic variation into a purportedly viable placeholder for variable drug response — to be used here and (...)
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography  
  40. Anna Mastroianni & Jeffrey Kahn (2001). The? Etv. Hastings Center Report 21:15.
     
    Export citation  
     
    My bibliography   1 citation  
  41.  4
    Jeffrey Kahn (2004). Genetic Counselors' Impact on the Genetics Revolution: Recommendations of an Informed Outsider. Bioethics Examiner 8.
    Direct download  
     
    Export citation  
     
    My bibliography  
  42.  7
    Tom L. Beauchamp, Howard Brody, Franklin G. Miller, Alexander S. Curtis, Martina Darragh, Patricia Milmoe, Ronald M. U. S. Green, Sharona Hoffman, Edmund G. Howe & Jeffrey P. Kahn (2003). By Author BAGHERI, Alireza. Criticism of “Brain. Kennedy Institute of Ethics Journal 13 (4):407-09.
    No categories
    Direct download  
     
    Export citation  
     
    My bibliography  
  43.  20
    Jeffrey P. Kahn (2007). Organs and Stem Cells: Policy Lessons and Cautionary Tales. Hastings Center Report 37 (2):11-12.
    Direct download (6 more)  
     
    Export citation  
     
    My bibliography  
  44.  10
    Joan Yess Kahn (1981). The Semiotic Crisis in Contemporary Hospitals. Semiotics:337-343.
    No categories
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography  
  45.  13
    Jonathan Kahn (2006). Race, Pharmacogenomics, and Marketing: Putting BiDil in Context. American Journal of Bioethics 6 (5):W1-W5.
    This article endeavors to place into context recent developments surrounding the United States Food and Drug Administration recent approval of BiDil? (isosorbide dinitrate/hydralazine hydrochloride) (NitroMed, Inc., Lexington, MA) as the first ever race-specific drug?in this case to treat heart failure in African Americans. It focuses in particular on both commercial incentives and statistical manipulation of medical data as framing the drive to bring BiDil to market as a race-specific drug. In current discourse about pharmacogenomics, targeting a racial audience is perceived (...)
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography  
  46.  14
    Jeffrey Kahn (2001). Can We Broker Eggs Without Making Omelets? American Journal of Bioethics 1 (4):14 – 15.
  47.  12
    Jonathan Kahn (2011). The Two (Institutional) Cultures A Consideration of Structural Barriers to Interdisciplinarity. Perspectives in Biology and Medicine 54 (3):399-408.
    The famous 1959 Two Cultures essay by C. P. Snow has become a foil for decades of discussions over the relation between science and the humanities. The problem of the “two cultures” is often framed in terms of how the particular epistemological claims or general intellectual orientations of particular individuals on either side of this purported divide obstruct interdisciplinary dialogue or cooperation. This formulation, however, is ultimately unsatisfying, because often it focuses narrowly on the intentions and arguments of individuals, without (...)
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography  
  48.  3
    Jonathan Kahn (2015). Review of Lundy Braun, Breathing Race Into the Machine: The Surprising Career of the Spirometer From Plantation to Genetics. [REVIEW] American Journal of Bioethics 15 (2):5-6.
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography  
  49.  9
    Journet D. Kahn (1951). The Origin of Human Rights. Proceedings of the American Catholic Philosophical Association 25:178-187.
    Direct download (4 more)  
     
    Export citation  
     
    My bibliography  
  50.  15
    Jonathon S. Kahn (2004). Religion and the Binding of the Souls of Black Folk. Philosophia Africana 7 (2):17-31.
    Direct download (3 more)  
     
    Export citation  
     
    My bibliography  
1 — 50 / 101